

Medical Device Innovator with Two FDA-Cleared Product Lines

Vycor Overview

About Vycor Medical

Vycor Medical provides minimal or non-invasive neurosurgical and neurotherapeutic solutions. Technologies have been validated by numerous independent practitioners and published clinical studies. IP portfolio of 61 patents and 11 pending. Public company with management as controlling shareholders (63%)

Two Divisions

Vycor Medical – ViewSite™ Brain Access System (VBAS™): a field-proven, minimally invasive neurosurgical device for accessing and evacuating intracerebral hemorrhages (ICH), blood clots, tumors and physical objects lodged in the brain, like shrapnel.

NovaVision - NovaVision Visual Restoration Therapy® (VRT): Only FDA-cleared therapy for restoration of vision loss as the result of stroke or brain damage. **NeuroEyeCoach®:** helps patient compensate for vision disorders as a result of stroke or brain damage (FDA registered).

High gross margin both divisions: 80%+

Sizeable addressable markets


ViewSite™



NovaVision®

Lead product ViewSite™ Brain Access System (VBAS) is a revolutionary neurosurgical device used to retract and gain access to a target within the brain e.g. tumor, other pathologies and other matters such as bullets or shrapnel fragments

NovaVision has the most comprehensive, commercially available and clinically supported family of complementary therapies that diagnose (VIDIT) and both **restore** (Visual Restoration Therapy® “VRT”) and **compensate** (NeuroEyeCoach™) for vision disorders as a result of stroke or brain damage. VRT is the **only FDA-cleared therapy** for the restoration of this type of vision loss



Disclaimer: This document is for informational purposes only; it should not be construed as an offer to buy or sell securities. No guarantee is made as to accuracy, completeness, or timeliness of information provided. This document includes "forward looking statements" as defined by the Securities & Exchange Commission (SEC). All statements, other than historical facts, that address activities, events or developments that will or may occur in the future are considered forward-looking and are subject to a number of assumptions, risks and uncertainties. Investors are cautioned any such statements are not guarantees of future performance and actual results may differ materially due to of many factors. For further information about forward-looking statements, please see the company's most recent 10-K, 10-Q and other filings with the SEC.

STRICTLY PRIVATE AND CONFIDENTIAL

Vycor Medical Division - ViewSite Brain Access System (VBAS)

Retractor damage is most acute and evident during approaches to deep-seated intracranial lesions, during which the surrounding white matter comprising the surgical corridor is vulnerable to retractor-induced damage, however retraction injury to brain tissue is a possibility whenever retraction is required. VBAS addresses this issue.

The ViewSite™ Surgical Access System (VBAS™) is a suite of clear cylindrical minimally invasive disposable devices that are clinically supported and shown to allow for speedier, safer and more economical brain surgeries, and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community.

VBAS has an extensive body of 29 peer-reviewed and 12 other clinical papers demonstrating the key advantages to surgeons and hospitals:

Less Invasive Procedure/Shorter OR time

Given the retractor's tubular elliptical shape, a large amount of white matter does not have to be resected since the retractor gently splits as it is advanced into white matter without further damage or transection. Clinical studies point to shorter OR times.

Reduction of Venous Pressure/Faster Patient Recovery

The tubular shape of the VBAS disperses retraction forces over a greater surface area than conventional blade retractors, which lowers the risk of ischemic complications resulting in fast wound healing and short patient recovery period.

Superior Field of View

Made of polished transparent polycarbonate, the VBAS significantly increases a surgeon's field of vision through a clear, visible and stable channel, allowing for continual monitoring of surrounding tissue and structures during insertion and surgery.

Improved Working Channel

The elliptical shape of the VBAS device provides a widened working channel in one axis to give the surgeon greater working room, while keeping the other axis smaller to minimize invasiveness.

More Accurate Target Access

Traditional retractor technology does not integrate well with IGS navigation systems. VBAS facilitates IGS use and the newly launched VBAS AC model locks the IGS pointer in place to allow vertical/horizontal alignment and single-handed navigation.

Avoiding Target Shift

Standard retractors pull on the brain's soft tissue. This pulling may cause the target area to shift. There is no target shift with VBAS as its elliptical shape distributes uniform pressure to the surrounding brain areas.

Hitherto the VBAS has been predominantly used for deep tumor access, however more recently neurosurgeons have started to use the device for access and drainage of ICH cases, which provides a much larger and exciting potential end market.

Vycor Medical is ISO 13485:2016 and MDSAP certified, and VBAS (and VBAS AC) has FDA 510(k) clearance, a Health Canada Medical License, and CE Marking for Europe (Class III), as well as regulatory approvals in a number of other international markets. The US is the Company's largest market (approx. 70% sales), and VBAS is approved for use in over 200 hospitals nationwide. The Company's other largest markets are Canada, Japan and the UK and international provides a significant area of opportunity for growth.

The Vycor division operates as a "virtual" company, sub-contracting manufacturing to US manufacturers and distributing through independent specialist distributors in the US and internationally.

There are 30 issued patents and 11 pending patents covering the product range, including some exciting in-development products.

STRICTLY PRIVATE AND CONFIDENTIAL

NovaVision

Every forty seconds someone has a stroke in the United States and there are approximately 8 million stroke survivors in the United States alone. Up to 30% of these experience a resultant vision disorder, up to 20% permanently. NovaVision's products are focused on Compensation and Restoration, with product offerings tailored to physicians, clinics and centers as well as direct to patients. Vision Restoration Therapy® (VRT®) is provided by NovaVision in a therapy suite with its NeuroEyeCoach® compensation therapy.

VRT:

- Is the only commercially available FDA-cleared therapy designed to restore vision loss due to neurological brain damage.
- Therapy is done at home on the patient's own computer and on their own schedule.
- Improvement does not depend on how long ago their vision loss occurred.
- VRT is performed twice daily, six days a week for approximately six months.

NeuroEyeCoach:

To carry out normal daily tasks, such as finding an object at home or on a supermarket shelf, you need to make effective eye movements. Unfortunately, in addition to a visual field loss, normal eye movements are often also affected after brain injury; which is what NeuroEyeCoach was created to address. Best evidence of its efficacy can be seen in the 300 peer-reviewed patient study (largest ever conducted on eye movement training) conducted by University of Aberdeen and University of Miami Miller School of Medicine, published in *Cortex*. This showed that patients who undertook the NEC therapy:

- Achieved major improvements in a short period of time.
- Experienced meaningful improvement in visual search performance (87% of patients) resulting in improvements in navigation skills and object finding.
- Increased the efficiency of a patient's eye movement and re-trains the patients' ability to make the most of their remaining vision; 80% had made less errors leading to real improvements in daily living

The program has been designed to be intuitive and user-friendly and not to be overly demanding; can be quickly completed in 2-4 weeks in comfort of their own home on patient's own computer or supervised in a rehabilitation environment.

Based around VRT and NeuroEyeCoach the Company has developed a broad range of flexible Medical Professional Product offerings:

NovaVision Professional Physician Model

NovaVision provides a model which enables physicians to register patients for NovaVision's VRT and NeuroEyeCoach therapies in their clinic or practice, monitor patients' progress during their therapy and meet with them to review results during or at the completion of therapy, as desired.

NovaVision Center Model

NovaVision provides a complete program suite for the rehab center and clinic market, which enables clinics to work with patients while in their care, both in-patient and out-patient. The Center Model comprises: VIDIT, a unique visual field diagnostic program; and NeuroEyeCoach.

NovaVision Optometrist Model

NovaVision provides a cloud-based model that enables optometrists and other eye-care professionals to perform the VIDIT diagnostic test and train patients with NeuroEyeCoach.

NovaVision's therapies and programs play into the move by health providers worldwide to promote digital health – whereby patients commence therapy in the clinic and continue it at home, reducing cost

NovaVision has 31 issued patents.